MedTrace Logo

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-05-17

Study results available
· View outcomes & findings →

Summary

This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.

Conditions

Interventions

DRUG

Ranibizumab

Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.

DRUG

Ranibizumab

Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Retina Vitreous Associates of Florida

    lead OTHER

Principal Investigators

  • David Eichenbaum, MD · Retina Vitreous Associates of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01476449 on ClinicalTrials.gov